{
    "nct_id": "NCT04570839",
    "official_title": "A Phase 1/2 Study Evaluating the Safety, Tolerability and Preliminary Antitumor Activity of COM701 in Combination With BMS-986207 (Anti-TIGIT Antibody) and Nivolumab in Subjects With Advanced Solid Tumors.",
    "inclusion_criteria": "* Histologically or cytologically confirmed, locally advanced or metastatic solid malignancy and has exhausted all available standard therapy or is not a candidate for the available standard therapy.\n* Eastern Cooperative Oncology Group (ECOG) performance status 0-1.\n* During dose escalation - Subjects who received prior therapy with anti-PD-1, anti-PD-L1, anti- CTLA-4, OX-40, CD137, etc., are eligible.\n\nDuring cohort expansion: All subjects must have measurable disease as defined by RECIST v1.1.\n\nExpansion Cohorts:\n\n* Cohort 1 (subjects with advanced epithelial ovarian, fallopian tube, or primary peritoneal carcinoma)\n* Subject must have platinum refractory/resistant ovarian cancer defined as refractoriness to platinum-containing regimen or disease recurrence < 6 months after completion of a platinum-containing regimen\n* Cohort 2 (endometrial cancer cohort)\n* Subjects with locally advanced or metastatic microsatellite stable endometrial cancer with disease recurrence or progression during or after prior therapy that included platinum-based chemotherapy.\n* Subjects must have documented MSS status by an approved test e.g. genomic testing, IHC for mismatch repair proficient.\n* Subjects must have received no more than 2 prior systemic cytotoxic therapies; there are no limits to the number of prior endocrine or antiangiogenic regimens\n* Cohort 3 (basket cohort, excludes tumor types in cohorts 1 and 2)\n* Tumor types with high expression of PVRL2 (determined by central testing).\n* Cohort 4 (Head and Neck cancer)\n* Histologically confirmed recurrent or metastatic HNSCC (oral cavity, oropharynx, larynx, hypopharynx, nasopharynx, paranasal sinus, nasopharyngeal)\n* Cohort 4a - IO naïve. Eligible subjects can be systemic therapy naïve (frontline) or platinum failure.\n* Cohort 4b - IO failure. No limitations on the number of prior lines of systemic therapy.\n\nKey\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Active autoimmune disease requiring systemic therapy in the last 2 years prior to the first dose of COM701.\n* Symptomatic interstitial lung disease or inflammatory pneumonitis.\n* History of immune-related events that lead to immunotherapy treatment discontinuation.\n* Untreated or symptomatic central nervous system (CNS) metastases.\n\nKey Exclusion Criteria For Dose Expansion Cohorts:\n\n* Cohort 1: Prior therapy with an anti-PD-1/PD-L1/2, COM701 (or any inhibitor of PVRIG), anti-TIGIT antibody, anti-CTLA-4 antibody, anti-OX-40 antibody, anti-CD137 antibody.\n* Cohort 2: Prior therapy with COM701 (or any inhibitor of PVRIG) or anti-TIGIT antibody. Subjects with MSI-H endometrial cancer are ineligible.\n* Cohort 3: Prior therapy with COM701 (or any inhibitor of PVRIG) or anti-TIGIT antibody are ineligible.\n* Cohort 4: Subjects who have received prior therapy with COM701 (or any inhibitor of PVRIG), anti-TIGIT antibody, anti-CTLA-4 antibody, anti-OX-40 antibody, anti-CD137 antibody. Subjects in cohort 4a must be IO-naïve.",
    "miscellaneous_criteria": "Key"
}